Work

Abstract CT200: Phase I dose-escalation study of ENPP1 inhibitor, vizenpistat, for the treatment of solid tumors

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct200

Authors: Mohan R. Kaadige, Alexis S. Larsen, Trason Thode, Margaux Steinbach, Scott Houston, Srinivas Kasibhatla, Jonathan Northrup, Sunil Sharma

Language: English

Topic: Adenosine and Purinergic Signaling

Subfield: Physiology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154739374

Cites:

Cited by:

Related to: